Advertisement

Hyperpigmented Patches

  • Yan Ling Kong
  • Emily Yiping Gan
Chapter

Abstract

  • Mastocytosis is divided into the systemic and skin-limited forms. The main subtypes of pediatric cutaneous mastocytosis include maculopapular cutaneous mastocytosis which includes urticaria pigmentosa, mastocytoma and diffuse cutaneous mastocytosis.

  • The presence of an elevated serum total tryptase level (≥20 ng/mL) reflects more extensive skin disease, higher risk of severe mast cell activation, and possible systemic involvement

  • Physical stimuli, emotional factors, infection, drugs and food may activate mast cells

  • In children, common triggers include temperature changes, irritability, fever and teething

  • Medications that may be effective in the treatment of cutaneous mastocytosis include H1 and H2 antihistamines, mast cell stabilizers like cromolyn sodium and leukotriene antagonists

Keywords

Mastocytosis Urticaria pigmentosa Mastocytoma Antihistamines Cromolyn sodium 

References

  1. 1.
    Meni C, Bruneau J, Georgin-Lavialle S, Le Sache de Peufeilhoux L, Damaj G, Hadj-Rabia S, Fraitag S, Dubreuil P, Hermine O, Bodemer C. Paediatric mastocytosis: a systematic review of 1747 cases. Br J Dermatol. 2015;172(3):642–51.CrossRefGoogle Scholar
  2. 2.
    Castells M, Metcalfe DD, Escribano L. Diagnosis and treatment of cutaneous mastocytosis in children: practical recommendations. Am J Clin Dermatol. 2011;12(4):259–70.CrossRefGoogle Scholar
  3. 3.
    Heinze A, Kuemmet TJ, Chiu YE, Galbraith SS. Longitudinal study of pediatric urticaria pigmentosa. Pediatr Dermatol. 2017;34(2):144–9.CrossRefGoogle Scholar
  4. 4.
    Horan RF, Austen KF. Systemic mastocytosis: retrospective review of a decade’s clinical experience at the Brigham and Women’s Hospital. J Invest Dermatol. 1991;96(3 Suppl):5S–13S; discussion S-4S, 60S–65SCrossRefGoogle Scholar
  5. 5.
    Moura DS, Georgin-Lavialle S, Gaillard R, Hermine O. Neuropsychological features of adult mastocytosis. Immunol Allergy Clin N Am. 2014;34(2):407–22.CrossRefGoogle Scholar
  6. 6.
    Alvarez-Twose I, Vano-Galvan S, Sanchez-Munoz L, Morgado JM, Matito A, Torrelo A, Jaen P, Schwartz LB, Orfao A, Escribano L. Increased serum baseline tryptase levels and extensive skin involvement are predictors for the severity of mast cell activation episodes in children with mastocytosis. Allergy. 2012;67(6):813–21.CrossRefGoogle Scholar
  7. 7.
    Valent P, Akin C, Escribano L, Fodinger M, Hartmann K, Brockow K, Castells M, Sperr WR, Kluin-Nelemans HC, Hamdy NA, Lortholary O, Robyn J, van Doormaal J, Sotlar K, Hauswirth AW, Arock M, Hermine O, Hellmann A, Triggiani M, Niedoszytko M, Schwartz LB, Orfao A, Horny HP, Metcalfe DD. Standards and standardization in mastocytosis: consensus statements on diagnostics, treatment recommendations and response criteria. Eur J Clin Investig. 2007;37(6):435–53.CrossRefGoogle Scholar
  8. 8.
    Kirsch R, Geboes K, Shepherd NA, de Hertogh G, Di Nicola N, Lebel S, Mickys U, Riddell RH. Systemic mastocytosis involving the gastrointestinal tract: clinicopathologic and molecular study of five cases. Mod Pathol. 2008;21(12):1508–16.CrossRefGoogle Scholar
  9. 9.
    Kettelhut BV, Berkebile C, Bradley D, Metcalfe DD. A double-blind, placebo-controlled, crossover trial of ketotifen versus hydroxyzine in the treatment of pediatric mastocytosis. J Allergy Clin Immunol. 1989;83(5):866–70.CrossRefGoogle Scholar
  10. 10.
    Johnson GJ, Silvis SE, Roitman B, Blumenthal M, Gilbert HS. Long-term treatment of systemic mastocytosis with histamine H2 receptor antagonists. Am J Gastroenterol. 1980;74(6):485–9.PubMedGoogle Scholar
  11. 11.
    Berg MJ, Bernhard H, Schentag JJ. Cimetidine in systemic mastocytosis. Drug Intell Clin Pharm. 1981;15(3):180–3.CrossRefGoogle Scholar
  12. 12.
    Horan RF, Sheffer AL, Austen KF. Cromolyn sodium in the management of systemic mastocytosis. J Allergy Clin Immunol. 1990;85(5):852–5.CrossRefGoogle Scholar
  13. 13.
    Tolar J, Tope WD, Neglia JP. Leukotriene-receptor inhibition for the treatment of systemic mastocytosis. N Engl J Med. 2004;350(7):735–6.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2020

Authors and Affiliations

  • Yan Ling Kong
    • 1
  • Emily Yiping Gan
    • 2
  1. 1.National Skin CentreSingaporeSingapore
  2. 2.Dermatology ServiceKK Women’s and Children’s HospitalSingaporeSingapore

Personalised recommendations